Rallybioの空売り状況は、投資家がRallybioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Rallybio (NASDAQ:RLYB) 株価情報, 空売り情報

RALLYBIO CORP

Rallybio

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Rallybio Corp

Perpetua Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.02) by 500 percent. This is a 140 percent decrease over losses of $(0.05) per share from the same period last year.

Earnings

Earnings Misses

News

PPTA

Perpetua Resources Q1 EPS $(0.12) Misses $(0.02) Estimate

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and maintains $7 price target.

Price Target

Analyst Ratings

OCGN

Chardan Capital Maintains Buy on Ocugen, Maintains $7 Price Target

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) affirms FY2025 Adj EPS guidance from $6.75-$7.75 to $6.75-$7.75 vs $7.41 analyst estimate..

Guidance

NRG Energy Affirms FY2025 Adj EPS Guidance of $6.75-$7.75 vs $7.41 Est

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) reported quarterly earnings of $2.68 per share which beat the analyst consensus estimate of $1.49 by 79.87 percent. This is a 16.02 percent increase over earnings of $2.31 per share from the same period last year. The company reported quarterly sales of $8.59 billion which beat the analyst consensus estimate of $7.83 billion by 9.69 percent. This is a 15.56 percent increase over sales of $7.43 billion the same period last year.

Earnings Beats

NRG Energy Q1 Adj. EPS $2.68 Beats $1.49 Estimate, Sales $8.59B Beat $7.83B Estimate

Needham analyst Laura Martin maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and raises the price target from $14 to $18.

MGNI

Needham Maintains Buy on Magnite, Raises Price Target to $18

Seagate Data Storage Technology Pte. Ltd. (the "Company"), a subsidiary of Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) ("Seagate"), today announced that the Company intends to offer, subject to market and other conditions, $400.0 million in aggregate principal amount of senior notes due 2030 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and in offshore transactions under Regulation S under the Securities Act. The Notes are expected to be guaranteed by Seagate, Seagate Technology Unlimited Company and Seagate HDD Cayman.
In connection with this offering, Seagate HDD Cayman issued a notice of conditional full redemption providing for the redemption (the "Redemption") of all of its outstanding 4.875% Senior Notes due 2027 (the "2027 Notes"), at a redemption price equal to 100% of the principal amount of the 2027 Notes, plus a "make-whole" premium set forth in the indenture governing the 2027 Notes, plus accrued and unpaid interest to, but excluding, the redemption date (the "Redemption Price"). The Redemption is conditioned upon receipt by the Company on or prior to the redemption date of net proceeds from one or more financing transactions in an amount, together with cash on hand, sufficient to pay the Redemption Price on or prior to the redemption date.
The Company intends to use the net proceeds from the offering of the Notes, together with cash on hand, to finance the Redemption and to pay related fees and expenses.

Seagate Subsidiary Intends To Offer $400M Senior Notes Due 2030

Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) today announced expanded coverage of the Garmin Navigation Database to include the South Pacific region, including Australia, New Zealand and surrounding countries. Previously available to aircraft owners and operators in the Americas and Europe, the Garmin Navigation Database delivers a new option for South Pacific region customers to incorporate the latest aviation navigation information into their Garmin avionics. Offered for a variety of Garmin aviation products, including integrated flight decks, navigators, flight displays, portables and more, the new Garmin Navigation Database for the South Pacific region introduces a variety of cost-effective ways to purchase database updates. This includes single updates, annual bundle options and OnePak&#x2122; subscriptions for all compatible avionics in an aircraft.
 &nbsp;

GRMN

Garmin Expands Aviation Navigation Coverage to Include South Pacific, Offering Cost-Effective Updates

Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and maintains $38 price target.

QURE

Chardan Capital Maintains Buy on uniQure, Maintains $38 Price Target

The Founder, CEO, and CIO of Ark Invest, Cathie Wood, has highlighted the rising applications of artificial intelligence and how it is poised to impact not only autonomous taxi networks and humanoid robots but also the health care space.
What Happened: According to ARK's proprietary Multiomics Flywheel, Wood highlighted in her recent X post that autonomous taxi networks and humanoid robots are likely to be the largest AI applications during the next five and ten years, respectively; however, &#8220;health care is likely to be the most profound.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While autonomous taxi networks and humanoid robots are likely to be the largest <a href="https://twitter.com/hashtag/AI?src=hash&amp;ref_src=twsrc%5Etfw">#AI</a> applications during the next five and ten years, respectively, health care is likely to be the most profound. Thank you <a href="https://twitter.com/NMDespotARK?ref_src=twsrc%5Etfw">@NMDespotARK</a> for thought leadership in the multiomics space! <a href="https://t.co/C33JfypivU">https://t.co/C33JfypivU</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1921291392271167893?ref_src=twsrc%5Etfw">May 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The post shared by Ark&#8217;s multiomics analyst, Nemo M Despot, underscored that &#8220;AI is powering a self-reinforcing loop that accelerates every aspect of multiomics—from generating biological data, to diagnosing diseases, to developing new drugs and cures.&#8221;
Multiomics is a biological analysis approach that integrates data from multiple &#8220;omic&#8221; fields, like genomics, transcriptomics, proteomics, and metabolomics, to gain an understanding of biological systems.
This integrated approach helps researchers uncover complex relationships, identify biomarkers, and ultimately understand the mechanisms behind disease and other biological processes.
He also highlights that companies like Twist Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 10X Genomics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) are developing increasingly powerful tools to sequence and analyze DNA faster and more cost-effectively.
Despot stated that AI-powered molecular diagnostics are transforming early disease detection and enabling precise stratification of individual patient biological profiles.
&#8220;AI leverages data from multiomic tools and diagnostics to design more effective drugs, delivering results with higher success rates more quickly and less expensively,&#8221; he said.
According to him, these next-generation therapies are:
<ul class="wp-block-list">
<li>Approximately 20 times more valuable than standard drugs.</li>
</ul>
<ul class="wp-block-list">
<li>Two to four times more effective than even today's best-in-class precision medicine.</li>
</ul>
<ul class="wp-block-list">
<li>The new cures can address even rare diseases economically.</li>
</ul>
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45340465/bill-ackman-slams-subsidies-for-contributing-to-37-trillion-national-debt-hails-trumps-drug-price-order">Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump&#8217;s Drug Price Order</a>
Why It Matters: Trump, in a Truth Social post, said that he will <a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">sign an executive order</a> on Monday at 9:00 a.m. ET, which will lead the prescription drug and pharmaceutical prices to drop by 30% to 80%.
&#8220;They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA! I will be instituting a MOST FAVORED NATION'S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World,&#8221; he added.
Trump also believes that healthcare costs in the U.S. will be reduced after this move, and it would save &#8220;trillions of dollars.&#8221;
This action by Trump is anticipated to most significantly <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">affect Medicare Part B drugs</a>, primarily outpatient prescriptions and biological products, as their prices are directly controlled by the Centers for Medicare &amp; Medicaid Services (CMS).
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Drug Name</th>
<th>Manufacturer(s)</th>
<th>Total Spending</th>
<th>Primary Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keytruda</td>
<td>Merck &amp; Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) 
<path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path>
<div jsname="ntFePb" class="GRl5yb a8pxAe" style="max-height: 120px; visibility: inherit;"></div>
<div></div>
</td>
<td>$4.0B</td>
<td>Cancer (various types)</td>
</tr>
<tr>
<td>Eylea</td>
<td>Regeneron Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>$3.4B</td>
<td>Macular degeneration</td>
</tr>
<tr>
<td>Prolia/Xgeva</td>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>$2.1B</td>
<td>Osteoporosis, bone metastases</td>
</tr>
<tr>
<td>Opdivo</td>
<td>Bristol-Myers Squibb Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>$2.0B</td>
<td>Cancer (various types)</td>
</tr>
<tr>
<td>Darzalex</td>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>$1.9B</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Avastin</td>
<td>Roche Holdings AG&nbsp;(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTCQX">RHHBY</a>)</td>
<td>$1.8B</td>
<td>Cancer (various types)</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Monday. The SPY was up 2.78% to $564.34, while the QQQ advanced 3.75% to $506.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Friday, the SPY was down 0.13% to $564.34, while the QQQ declined 0.066% to $487.97
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45341850/economists-warn-of-empty-shelves-if-goods-stop-coming-from-china-amid-falling-inventory-to-sales-ratio-and-potential-tariffs">Economists Warn Of &#8216;Empty Shelves&#8217; If Goods Stop Coming From China Amid Falling Inventory-To-Sales Ratio And Potential Tariffs </a></li>
</ul>
Photo Courtesy: PeopleImages- Yuri A On Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Markets

ETFs

General

AMGN

ILMN

REGN

RHHBY

TWST

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots

Needham analyst Mayank Tandon reiterates PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) with a Buy and maintains $90 price target.

Reiteration

Needham Reiterates Buy on PAR Technology, Maintains $90 Price Target

BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(4.16) by 63.94 percent. This is a 89.22 percent increase over losses of $(13.92) per share from the same period last year. The company reported quarterly sales of $168.00 thousand which missed the analyst consensus estimate of $426.67 thousand by 60.63 percent. This is a 71.13 percent decrease over sales of $582.00 thousand the same period last year.

BTAI

BioXcel Therapeutics Q1 EPS $(1.50) Beats $(4.16) Estimate, Sales $168.00K Miss $426.67K Estimate

Apogee Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.25) by 24 percent. This is a 48.44 percent decrease over losses of $(0.64) per share from the same period last year.

APGE

Apogee Therapeutics Q1 EPS $(0.95) Beats $(1.25) Estimate

<ul>
<li>Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)</li>
<li>Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025</li>
<li>SYMMETRY study results published in New England Journal of Medicine</li>
<li>Raised $402.5 million in gross proceeds in a follow-on public offering in January 2025,&nbsp;resulting in reserves of cash, cash equivalents, and marketable securities of $1,128 million at March 31, 2025</li>
</ul>

AKRO

Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028

<a href="https://www.globenewswire.com/Tracker?data=PjCTSVgCkDiVs5e9YCoOHU0TgyVMvy1h5xWtw75s1DwD0uo9CHHJsqoASOWAmvdSJabJSfzaFt2XUqJDdR0Q7g==">Viasat, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>), a global leader in satellite communications, has confirmed the GX10A and GX10B satellite payloads are now available to deliver services for government customers, with commercial maritime and aviation services anticipated to follow throughout fiscal year 2026. Viasat successfully completed in-orbit testing of the payloads late last year and government services are now available.
Launched from Vandenberg Space Force Base in August 2024, the GX10A and GX10B payloads are housed on Space Norway's Arctic Satellite Broadband Mission spacecraft — ASBM-1 and ASBM-2. The satellites feature hosted payloads for the Norwegian Military and the U.S. Government, as well as a radiation monitoring capability for the European Commission. For Viasat, the GX10A and GX10B payloads are aimed to provide broadband satellite coverage over the Arctic region for government and commercial customers.

VSAT

Viasat's New Arctic Satellites Go Live for US Government Use, With Commercial Rollout Set for 2026

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54252800&amp;newsitemid=20250512731729&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=c09d64a6df2c8aec7de70fcaf5351a15">Alnylam Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia.
The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the "Hottest Trials and Trial Updates 1" session.
Data from the HELIOS-B study supported the recent approvals of AMVUTTRA&#xAE; (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of vutrisiran for the same indication. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year.
Additional updates to be presented include the design and rationale of the TRITON-CM Phase 3 study of nucresiran (ALN-TTRsc04), an investigational next-generation TTR silencer, in patients with ATTR-CM, as well as an additional analysis from the HELIOS-B study of vutrisiran in patients with ATTR-CM who experienced disease progression while being treated with tafamidis.

ALNY

Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress

AEVA

Aeva Receives First Purchase Orders For More Than 1,000 Eve 1 Sensors From Automation Companies

<a href="https://www.globenewswire.com/Tracker?data=GWR2eGLoIi_p5untQNvqzi8pVzHF9jvBOmr9J9xvhpbL1C2bsvHbKy9WkzD1RwLlPd95txg4UThpe66PORAgnw==">Classiq</a> today announced raising $110 million in Series C funding, the largest ever for a quantum software company. The round was led by <a href="https://www.globenewswire.com/Tracker?data=Mgsm0Xq5pG57VLfeecZLoqIJnh61ux94L2fD5v4QNJNVbkRBXiEoWWZ-V9hWxcBE_GLVSdgg-HhwZuiR_Hsv6QQU2VCoGzrQwCyAQnc7Gvc=">Entrée Capital</a>, with participation from Norwest, NightDragon, funds managed by Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>), Clal, Neva SGR, Phoenix, Team8, IN Venture, Wing, HSBC, Samsung Next and QBeat, as well as other new and existing investors.
This investment brings Classiq's total funding to $173 million, positioning the company to meet growing demand by significantly scaling its go-to-market, customer success and R&amp;D teams. Classiq will expand its global footprint to broaden its leading role in national quantum initiatives and as a cornerstone of the quantum ecosystem.

HLNE

Classiq Announces Raising $110M In Series C Quantum Software Funding

D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) with a Buy and raises the price target from $14 to $27.

MDCX

D. Boral Capital Maintains Buy on Medicus Pharma, Raises Price Target to $27

WIIM

KDLY

KindlyMD shares are trading higher after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.

<ul>
<li>MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025</li>
<li>MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and&nbsp;co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025.</li>
<li>MET-097o, an oral formulation of MET-097i, has been accelerated&nbsp;and alternate oral candidate MET-224o is on track, with four-week data&nbsp;for selected lead expected in late 2025.</li>
</ul>

Comments

Rallybio

空売り

Rallybio (NASDAQ:RLYB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル